|1.||Privat, Alain: 3 articles (01/2013 - 05/2002)|
|2.||Privat, A: 3 articles (11/2007 - 01/2000)|
|3.||D'Arbigny, P: 3 articles (06/2004 - 11/2000)|
|4.||Gaviria, M: 3 articles (01/2001 - 01/2000)|
|5.||Vignon, Jacques: 2 articles (01/2013 - 05/2002)|
|6.||Balali-Mood, Mahdi: 2 articles (06/2012 - 01/2012)|
|7.||Hirbec, H: 2 articles (11/2007 - 01/2001)|
|8.||d'Arbigny, P: 2 articles (08/2000 - 01/2000)|
|9.||Haton, H: 2 articles (08/2000 - 01/2000)|
|10.||Ohanna, F: 2 articles (08/2000 - 01/2000)|
|1.||Spinal Cord Injuries (Spinal Cord Injury)
11/01/2000 - "Efficacy of a new neuroprotective agent, gacyclidine, in a model of rat spinal cord injury."
05/01/2002 - "Obtaining reliable and specific pharmacological tools for those binding sites is of particular interest, since it is likely that they play a substantial role in the low neurotoxicity, and therefore tolerability, of gacyclidine, a new neuroprotective drug currently evaluated in clinical trials for the treatment of brain and spinal cord injuries."
01/01/2001 - "Distribution of gacyclidine enantiomers after experimental spinal cord injury in rats: possible involvement of an active transport system."
08/25/2000 - "The aim of this study was to analyze the optimal time-window for neuroprotection by a novel NMDA antagonist, Gacyclidine, after experimental spinal cord injury, in terms of its functional, histopathological and electrophysiological effects. "
01/01/2000 - "The aim of this study was to evaluate the efficacy, optimal dose, and optimal time-window of gacyclidine, a novel N-methyl-D-aspartate (NMDA) receptor antagonist, in terms of its functional, histopathological, and electrophysiological effects after experimental spinal cord injury. "
08/01/1999 - "However, only gacyclidine is able to ensure complete management of nerve agent poisoning for rapid normalization of EEG activity, clinical recovery and neuroprotection. "
03/01/1999 - "Overall, in the case of severe OP-poisoning, gacyclidine represents a promising adjuvant therapy to the currently available polymedication to ensure optimal management of organophosphate poisoning in man. "
01/01/1998 - "GK-11 represents a promising adjuvant therapy to the currently available emergency polymedication to ensure optimal management of organophosphate poisoning in man. "
01/01/1998 - "Nerve agent poisoning in primates: antilethal, anti-epileptic and neuroprotective effects of GK-11."
01/01/1997 - "GK 11: promising additional neuroprotective therapy for organophosphate poisoning."
|3.||Brain Injuries (Brain Injury)
06/01/2001 - "Beaufour-Ipsen is developing gacyclidine (GK-11) for the potential treatment of traumatic brain injury. "
01/01/2001 - "In traumatic brain injury models gacyclidine improves also behavioral parameters and neuronal survival. "
06/01/2004 - "The aim of this study was to assess the safety and efficacy of intravenous (IV) injections of gacyclidine, a novel NMDA receptor antagonist, for neurological and functional recovery following acute traumatic brain injury. "
05/01/2010 - "After constant perfusion of gacyclidine for 40-63 h, four out of six patients experienced a temporary relief from their tinnitus. "
05/01/2010 - "Gacyclidine might present a potent drug for the suppression of sensorineural tinnitus in humans and therefore should be considered for future double-blinded, placebo-controlled clinical trials. "
05/01/2010 - "Thus, we thought that patients with therapy-resistant sensorineural tinnitus might benefit from a local therapy with gacyclidine. "
05/01/2010 - "Experiments in guinea pigs have shown that local administration of gacyclidine to the cochlea can suppress salicylate-induced tinnitus. "
05/01/2010 - "Effects of extracochlear gacyclidine perfusion on tinnitus in humans: a case series."
|5.||Body Weight (Weight, Body)
|2.||Dizocilpine Maleate (Dizocilpine)
|6.||pralidoxime (Protopam Chloride)
|7.||gacyclidine (GK 11)
|8.||Complement System Proteins (Complement)